keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/29452759/feasibility-study-of-weekly-nanoparticle-albumin-bound-paclitaxel-150-mg-m-2-followed-by-fluorouracil-epirubicin-and-cyclophosphamide-therapy-as-neoadjuvant-chemotherapy-for-her2-negative-breast-cancer
#1
Yasuyuki Kojima, Hisanori Kawamoto, Toru Nishikawa, Ryosuke Hayami, Arata Shimo, Ei Haku, Kyoko Akiyama, Koichiro Tsugawa
BACKGROUND: Although several studies have shown efficacy of nanoparticle albumin-bound (nab) paclitaxel use as a neoadjuvant treatment in breast cancer, dosage and schedules were varied or used in combination and the data are still limited for weekly regimens. We evaluated the feasibility of weekly nab-paclitaxel followed by FEC (5-FU [fluorouracil], epirubicin, and cyclophosphamide) treatment feasibility as neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS: Thirty-three patients with no previous chemotherapy were enrolled to receive nab-paclitaxel 150 mg/m 2 the first 3 of 4 weeks (3q4w) followed by FEC as neoadjuvant treatment...
January 11, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29445301/comparative-effectiveness-of-early-line-nab-paclitaxel-vs-paclitaxel-in-patients-with-metastatic-breast-cancer-a-us-community-based-real-world-analysis
#2
Reshma L Mahtani, Monika Parisi, Stefan Glück, Quanhong Ni, Siyeon Park, Corey Pelletier, Claudio Faria, Fadi Braiteh
Background: Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness of nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer using data from an electronic medical record database from community practices across the USA. Methods: We performed a retrospective cohort study using fully de-identified data from an independent US electronic medical record platform of patients with metastatic breast cancer initiating single-agent nab -paclitaxel or paclitaxel as a first- or second-line treatment from December 1, 2010 to October 6, 2014...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29435178/inhibition-of-the-mek-erk-pathway-augments-nab-paclitaxel-based-chemotherapy-effects-in-preclinical-models-of-pancreatic-cancer
#3
Niranjan Awasthi, Sheena Monahan, Alexis Stefaniak, Margaret A Schwarz, Roderich E Schwarz
Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the ERK cascade have been implicated as drivers of PDAC. Inhibition of downstream targets in the RAS-MAPK cascade such as MEK remains a promising therapeutic strategy. The efficacy of trametinib (Tra), a small molecule inhibitor of MEK1/2 kinase activity, in combination with nab-paclitaxel-based chemotherapy was evaluated in preclinical models of PDAC...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29434168/compatibility-and-stability-of-nab-paclitaxel-in-combination-with-other-drugs
#4
Naomi Mizuta, Tsutomu Nakagawa, Kazuhiro Yamamoto, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Ikuko Yano, Hironobu Minami, Midori Hirai
Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the compatibility and stability of solutions containing nab-paclitaxel and other drugs, including gemcitabine hydrochloride, carboplatin, dexamethasone sodium phosphate, granisetron hydrochloride, and palonosetron hydrochloride. We visually examined changes in appearance, pH, and concentration of the mixed solutions of nab-paclitaxel and other drugs for up to 24 h...
July 20, 2017: Kobe Journal of Medical Sciences
https://www.readbyqxmd.com/read/29434143/the-safety-and-efficacy-of-treatment-with-nab-paclitaxel-and-carboplatin-for-patients-with-advanced-squamous-non-small-cell-lung-cancer-concurrent-with-idiopathic-interstitial-pneumonias
#5
Tetsuo Fujita, Takuma Hiroishi, Kohei Shikano, Asako Yanagisawa, Noriko Hayama, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Hiroshi Tabeta, Sukeyuki Nakamura
Background Although lung squamous cell carcinoma (SCC) accounts for 20%-30% of lung cancer cases, new treatment options are limited. The CA031 study showed that nanoparticle albumin-bound-paclitaxel (nab-PTX) plus carboplatin produced a significantly higher overall response rate (41%) than solvent-based paclitaxel plus carboplatin in patients with lung SCC. However, the safety and efficacy of combination chemotherapy of nab-PTX and carboplatin has not yet been established for patients with concurrent lung SCC and idiopathic interstitial pneumonias (IIPs)...
February 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29416938/complete-response-in-advanced-breast-cancer-patient-treated-with-a-combination-of-capecitabine-oral-vinorelbine-and-dasatinib
#6
V Sgroi, M Bassanelli, M Roberto, E Iannicelli, R Porrini, P Pellegrini, A Tafuri, P Marchetti
Background: Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonstrated to be effective and safe in patients with advanced breast cancer pretreated with anthracycline. Furthermore, some studies assessed the activity of dasatinib, an oral tyrosine kinase inhibitor that inhibits five oncogenic tyrosine kinase families, alone or in combination with different chemotherapy in patients affected with advanced breast cancer...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29394852/-a-case-report-of-curative-surgery-for-pancreatic-ductal-adenocarcinoma-with-peritoneal-dissemination-after-gemcitabine-chemotherapy
#7
Yoshitoshi Ichikawa, Daisaku Yamada, Hidetoshi Eguchi, Yoshifumi Iwagami, Takehiro Noda, Tadafumi Asaoka, Hiroshi Wada, Koichi Kawamoto, Kunihito Gotoh, Shogo Kobayashi, Mitsuaki Tatsumi, Misa Takeyari, Masaki Mori, Yuichiro Doki
A 70-year-old man was diagnosed with pancreatic ductal adenocarcinoma(PDAC)with peritoneal dissemination and received systemic chemotherapy of gemcitabine(GEM)plus nab-paclitaxel. Since the patient could not continue the regimen due to an adverse event of liver dysfunction, he was administered GEM alone except for the first administration. GEM monotherapy resulted in remarkable anti-tumor effects with a distinct decrease of both tumor markers and size. Peritoneal metastases were not detected in images after 12 courses of the GEM regimen, and the vanished tumor metastasis in images was maintained until 16 courses were administered...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394808/-long-term-survival-after-multidisciplinary-treatment-for-resected-pancreatic-adenocarcinoma-with-recurrence-of-pulmonary-metastases-a-case-report
#8
Tadashi Tsukamoto, Makoto Takahama, Shintaro Kodai, Akishige Kanazawa, Takaaki Hori, Ryoji Kaizaki, Satoshi Takatsuka, Ryushi Komatsu
Recent studies indicated that isolated pulmonary metastases could define a favorable subgroup in metastatic pancreatic cancer. We report a case of isolated pulmonary metastases after curative resection of pancreas head cancer treated with chemotherapy and pulmonary metastasectomy survived for 79 months after recurrence. A 72-year-old male underwent pancreatoduodenectomy for pancreas head cancer. Adjuvant chemotherapy was done with gemcitabine hydrochloride (GEM)for 6 months and then S-1 for 2 months. Twenty-seven months after surgery, 2 small metastatic nodules in the left lung was detected...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394807/-a-case-of-successful-adjuvant-surgery-for-the-pancreas-head-cancer-with-peritoneal-metastasis
#9
Yukie Kyakumoto, Tatsuyuki Takadate, Masamichi Mizuma, Tatsuo Hata, Masahiro Iseki, Hideo Ohtsuka, Naoaki Sakata, Kei Nakagawa, Takanori Morikawa, Hiroki Hayashi, Fuyuhiko Motoi, Takeshi Naitoh, Atsushi Kanno, Tooru Shimosegawa, Michiaki Unno
We report a case of the pancreas head cancer with peritoneal metastasis, which was resected curatively after chemotherapy. A6 6-year-old male was referred to our hospital for the treatment of biliary stenosis. The serum CA19-9 level was elevated and abdominal CT scan showed stenosis of distal bile duct. By laparotomy, we noticed mass in the head of the pancreas with 8mm of the seeding nodule in a diameter at jejunal mesentery which was diagnosed as adenocarcinoma by intraoperative frozen sections. Therefore, the patient was diagnosed as pancreas head cancer with peritoneal metastasis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394800/-a-case-of-unresectable-locally-advanced-pancreatic-cancer-resulted-in-r0-surgery-after-chemotherapy
#10
Yu Sasaki, Hokahiro Katayama, Yohei Hosoda, Izumi Komoto, Takashi Sugimoto, Kazuhiro Yanagihara, Utae Katsushima, Jun Kawai, Hidenori Kiyochi, Kazuhiro Nishiyama, Asami Okabe, Yu Oshima, Shoji Tsunekawa, Nobuko Ogura, Yoshiro Taki
A 67-year-old man visited our hospital for jaundice. Abdominal dynamic CT showed the hypovascular tumor at the head of the pancreas that surrounded superior mesenteric artery(SMA)at an angle of 220 degree. No metastasis in lymph nodes and other organs was observed. We diagnosed the tumor unresectable locally advanced(UR-LA)pancreatic cancer. Chemotherapy was administered with gemcitabine and nab-paclitaxel(GEM+nab-PTX)and achieved partial response. Regression in size and in range around SMA to an angle of 150 was observed...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394789/-a-case-of-gemcitabine-and-nab-paclitaxel-therapy-for-multiple-metastatic-pancreatic-cancer
#11
Yusuke Takashima, Jun Shibamoto, Yukino Kawamura, Maiko Nishida, Hidekazu Hiramoto, Fumiaki Ochi, Masahiro Tsujiura, Susumu Nakashima, Junshin Fujiyama, Mamoru Masuyama
Pancreatic cancer is one of the leading causes of cancer-related death in Japan. Nab-paclitaxel(nab-PTX)and gemcitabine( GEM)combination chemotherapysignificantlyimproved overall survival in a phase III trial(MPACT). This combination chemotherapyhas become one of the first-line treatments for patients with metastatic pancreatic cancer since December 2014. We report a case of a patient who underwent this chemotherapyfor recurrence of pancreatic head cancer. A 64-yearold man, who underwent curative resection of pancreatic cancer 2 years ago, relapsed with multiple lung metastases and a para-aortic nodal metastasis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394759/-a-case-of-pathological-complete-response-following-neoadjuvant-chemotherapy-with-gemcitabine-plus-nab-paclitaxel-in-borderline-resectable-pancreatic-cancer
#12
Noriyuki Ohno, Makoto Ishida, Kenji Ohnishi, Katsuji Sawai, Shinsuke Tabata, Masaaki Deguchi, Tatsumi Kitajima, Yasuharu Kaizaki
We report a resected case with a pathological complete response(pCR)after neoadjuvant chemotherapy for borderline resectable pancreatic cancer(BRPC). A 67-year-old woman who had been treated for type 2 diabetes mellitus in our hospital presented with an exacerbation of diabetes. An abdominal CT scan confirmed a hypovascular mass in the pancreas body consistent with BRPC. After 3 courses of chemotherapy with gemcitabine plus nab-paclitaxel(GnP), her elevated DUPAN-2 level normalized. A follow up CT scan revealed that the tumor had decreased in size, and no distant metastasis was detected...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394630/-neoadjuvant-folfirinox-for-unresectable-adenocarcinoma-of-the-pancreas-a-case-report
#13
Toshiya Ochiai, Hiroyuki Inoue, Hiroki Nakatsuji, Nobuyuki Watanabe, Atsushi Yoshiyama, Hiroshi Ito, Atsushi Toma, Kenji Nakamura
A 38-year-old male presented to our hospital with complaint of vomiting. A CT demonstrated a mass sized 42mm in the pancreatic head invading to the duodenum and a liver mass sized 15mm in the medial segment. Biopsy revealed adenocarcinoma. Due to liver metastasis, he was deemed surgically unresectable. He was started on FOLFIRINOX therapy after gastrojejunum bypass operation. After 15 courses of the therapy, restaging showed a decrease in pancreatic tumor size and a disappearance of a liver mass along with PET-CT revealing no FDG-avid uptake...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394594/-multidisciplinary-therapy-with-gemcitabine-and-nab-paclitaxel-for-unresectable-pancreatic-cancer
#14
Fuyuhiko Motoi, Tatsuyuki Takadate, Shimpei Maeda, Kyohei Ariake, Kunihiro Masuda, Masaharu Ishida, Koji Fukase, Masamichi Mizuma, Hideo Ohtsuka, Naoaki Sakata, Hiroki Hayashi, Kei Nakagawa, Takanori Morikawa, Takeshi Naitoh, Michiaki Unno
Gemcitabine with nab-paclitaxel(GN)shows promisinganti -tumor effect and has been established standard regimen for metastatic pancreatic cancer(PC). Conversion surgery(CS), recently reported about initially unresectable PC with favorable response to non-surgical treatment, might provide long-term survival. The aim of this study is to evaluate the efficacy of multi-modal treatment includingCS after GN therapy for initially unresectable PC. From 2015 to 2016, 29 initially unresectable PC treated with chemotherapy includingGN were eligible for the retrospective analysis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29393478/co-treatment-with-gemcitabine-and-nab-paclitaxel-exerts-additive-effects-on-pancreatic-cancer-cell-death
#15
Ilaria Passacantilli, Valentina Panzeri, Francesca Terracciano, Gianfranco Delle Fave, Claudio Sette, Gabriele Capurso
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine. However, relapse almost invariably occurs and most patients develop metastatic, incurable disease. The aim of the present study was to assess the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) alone or in combination with gemcitabine in PDAC cell lines displaying different degrees of sensitivity to gemcitabine treatment...
January 25, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29390506/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-monotherapy-as-second-line-therapy-of-cytotoxic-anticancer-drugs-in-patients-with-advanced-non-small-cell-lung-cancer
#16
Masaki Anzai, Miwa Morikawa, Takehiro Okuno, Yukihiro Umeda, Yoshiki Demura, Tomoaki Sonoda, Makiko Yamaguchi, Kiyoshi Kanno, Kohei Shiozaki, Shingo Ameshima, Masaya Akai, Tamotsu Ishizuka
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC). METHODS: A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29387403/prospective-validation-of-patient-fatigue-questionnaire-facit-f-for-fatigue-assessment-in-nab-paclitaxel-plus-gemcitabine-therapy
#17
Ken-Ichi Okada, Seiko Hirono, Manabu Kawai, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Masaki Ueno, Shinya Hayami, Toshio Shimokawa, Hiroki Yamaue
Following the recent introduction of a stronger regimen for pancreatic carcinoma, patients undergoing chemotherapy present high incidences of fatigue. The feasibility and validity of evaluating fatigue by questionnaire for patients with unresectable pancreatic cancer (URPC) receiving this recent regimen of chemotherapy remains unclear. Enrolled patients completed the Functional Assessment of Cancer Therapy-Fatigue questionnaire (FACIT-F, version 4), a questionnaire regarding additional concerns, a numerical rating scale test concerning loss of appetite, an evaluation of degree of pain and sensory disorder, and the Patient Neurotoxicity Questionnaire (PNQ) before undergoing nab-paclitaxel plus gemcitabine therapy...
January 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29362902/a-phase-i-dose-escalation-trial-of-nab-paclitaxel-and-fixed-dose-radiation-in-patients-with-unresectable-or-borderline-resectable-pancreatic-cancer
#18
Jacob E Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter J O'Dwyer, Mark O'Hara, Kim A Reiss, Ursina Teitelbaum, Paul Wissel, Jeffrey A Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Doucette, John N Lukens, John P Plastaras, James M Metz, Edgar Ben-Josef
PURPOSE: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of approximately 16 months. Novel methods to improve outcomes are needed. Nab-paclitaxel (Abraxane) has shown efficacy in pancreatic cancer and is FDA-approved for metastatic disease in combination with gemcitabine. Nab-paclitaxel is also a promising radiosensitizer based on laboratory studies, but it has never been clinically tested with definitive radiotherapy for locally advanced pancreatic carcinoma...
January 23, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29353164/a-phase-ii-study-of-nab-paclitaxel-in-combination-with-ramucirumab-in-patients-with-previously-treated-advanced-gastric-cancer
#19
Hideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, Atsuo Takashima, Kensei Yamaguchi, Norisuke Nakayama, Takehiro Takahashi, Eiji Oki, Mizutomo Azuma, Tomohiro Nishina, Shuichi Hironaka, Yoshito Komatsu, Kohei Shitara
BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel was developed to improve paclitaxel solubility and does not need premedication to avoid infusion-related reactions associated with solvent-based (sb)-paclitaxel. We conducted a phase II trial to investigate the efficacy and safety of nab-paclitaxel plus ramucirumab combination therapy for previously treated advanced gastric cancer. PATIENTS AND METHODS: Patients with unresectable advanced gastric cancer refractory to first-line chemotherapy were administered nab-paclitaxel 100 mg/m2 intravenously on days 1, 8 and 15, plus ramucirumab 8 mg/kg intravenously on days 1 and 15 of a 28-day cycle...
January 17, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29348852/reduced-fbxw7-expression-in-pancreatic-cancer-correlates-with-poor-prognosis-and-chemotherapeutic-resistance-via-accumulation-of-mcl1
#20
Norihiro Ishii, Kenichiro Araki, Takehiko Yokobori, Dorgormaa Gantumur, Takahiro Yamanaka, Bolag Altan, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Norio Kubo, Yasuo Hosouchi, Hiroyuki Kuwano, Ken Shirabe
Pancreatic cancer is a highly malignant tumor type with poor outcomes, and elucidation of the mechanisms involved in cancer progression and therapeutic resistance is critical. FBXW7 is a key regulator of tumor malignant potential, and its substrate MCL1 regulates therapeutic resistance in human malignancies. Therefore, determination of the relevance of FBXW7 expression is critical for improving patient outcomes. In this study, we investigated the function and clinical significance of FBXW7 in pancreatic cancer...
December 22, 2017: Oncotarget
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"